242 related articles for article (PubMed ID: 15851793)
21. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
22. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
23. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
[TBL] [Abstract][Full Text] [Related]
24. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
25. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
26. Manage skin toxicities associated with EGFR inhibitors.
Becze E
ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
[No Abstract] [Full Text] [Related]
27. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
28. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
33. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
Eaby B; Culkin A; Lacouture ME
Clin J Oncol Nurs; 2008 Apr; 12(2):283-90. PubMed ID: 18390464
[TBL] [Abstract][Full Text] [Related]
34. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
35. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
36. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.
Chu CY; Chen KY; Wen-Cheng Chang J; Wei YF; Lee CH; Wang WM
J Formos Med Assoc; 2017 Jun; 116(6):413-423. PubMed ID: 28351555
[TBL] [Abstract][Full Text] [Related]
37. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
39. Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
Homey B; Gerber PA; Wollenberg A; Dirschka T; Hassel JC; Bölke E; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2012 Aug; 10(8):559-63. PubMed ID: 22672156
[TBL] [Abstract][Full Text] [Related]
40. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]